Search - tctmd.com

Displaying 1 - 20 of 36

Sort: Relevancy | Date

News Daily News

DETECT: No Long-term Harm From Paclitaxel Devices in PAD

L.A. McKeown

March 25, 2024

News Conference News CRT 2024

Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries

L.A. McKeown

March 14, 2024

News Daily News

UK Cardiac Audit Reveals Some Good, Some ‘Appalling’ Trends in PCI

L.A. McKeown

February 06, 2024

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

L.A. McKeown

October 25, 2023

News Daily News

Long-term Data Support Paclitaxel-Coated Balloons for In-Stent Restenosis

Michael O'Riordan

February 24, 2023

News Conference News

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

L.A. McKeown

November 18, 2022

News Conference News EuroPCR 2022

Long-term Outcomes With PCI and CABG: More Analyses to Stir the Pot

Michael O'Riordan

May 23, 2022

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Conference News ACC 2021

Even With Stent Cards, Patients Often Hazy on PCI Details Years Later

Michael O'Riordan

May 11, 2021

News Daily News

More Risk of Death—All, Cardiac, and Noncardiac—With PCI Over Surgery: Meta-analysis

Michael O'Riordan

October 23, 2020

News Conference News TCT 2020

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

L.A. McKeown

October 22, 2020

News Daily News

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Michael O'Riordan

September 16, 2020

News Daily News

Better Outcomes, Including Mortality, With IVUS-Guided PCI: Medicare Analysis

Michael O'Riordan

August 18, 2020

News Daily News

German Analysis Supports Long-term Safety of Paclitaxel-Based Therapies

L.A. McKeown

October 09, 2019

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

L.A. McKeown

March 01, 2019

News Daily News

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

L.A. McKeown

February 13, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Daily News

STEMI Care and Outcomes Still Affected by Socioeconomic Status, Insurance

Yael L. Maxwell

January 09, 2019

News Conference News TCT 2018

TALENT: Indian-Made Supraflex DES Stands Up Well Against Xience in All-Comers

Todd Neale

September 22, 2018

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

Advertisement

DETECT: No Long-term Harm From Paclitaxel Devices in PAD

Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries

UK Cardiac Audit Reveals Some Good, Some ‘Appalling’ Trends in PCI

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

Long-term Data Support Paclitaxel-Coated Balloons for In-Stent Restenosis

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

Long-term Outcomes With PCI and CABG: More Analyses to Stir the Pot

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

Even With Stent Cards, Patients Often Hazy on PCI Details Years Later

More Risk of Death—All, Cardiac, and Noncardiac—With PCI Over Surgery: Meta-analysis

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Better Outcomes, Including Mortality, With IVUS-Guided PCI: Medicare Analysis

German Analysis Supports Long-term Safety of Paclitaxel-Based Therapies

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

STEMI Care and Outcomes Still Affected by Socioeconomic Status, Insurance

TALENT: Indian-Made Supraflex DES Stands Up Well Against Xience in All-Comers

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content